These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 3712382

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. (+)-UH 232 and (+)-UH 242: novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors.
    Svensson K, Hjorth S, Clark D, Carlsson A, Wikström H, Andersson B, Sanchez D, Johansson AM, Arvidsson LE, Hacksell U.
    J Neural Transm; 1986; 65(1):1-27. PubMed ID: 3083041
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Conditioned reinforcing effects of 8-hydroxy-2-(di-N-propylamino) tetralin: involvement of 5-hydroxytryptamine 1A and D1 dopamine receptors.
    Shippenberg TS.
    Neurosci Lett; 1991 Jan 02; 121(1-2):136-8. PubMed ID: 1826942
    [Abstract] [Full Text] [Related]

  • 25. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    Seiler MP, Markstein R.
    Mol Pharmacol; 1984 Nov 02; 26(3):452-7. PubMed ID: 6238231
    [Abstract] [Full Text] [Related]

  • 26. Assessment of a potential dopaminergic prodrug moiety in several ring systems.
    Cannon JG, Furlano DC, Dushin RG, Chang YA, Baird SR, Soliman LN, Flynn JR, Long JP, Bhatnagar RK.
    J Med Chem; 1986 Oct 02; 29(10):2016-20. PubMed ID: 3761320
    [Abstract] [Full Text] [Related]

  • 27. A stereochemical and conformational model of dopaminergic agonist and antagonist activity: further evaluation.
    Froimowitz M, Baldessarini RJ.
    J Pharm Sci; 1987 Jul 02; 76(7):557-64. PubMed ID: 3668819
    [Abstract] [Full Text] [Related]

  • 28. Occurrence and pharmacological significance of metabolic ortho-hydroxylation of 5- and 8-hydroxy-2-(di-n-propylamino)tetralin.
    Wikström H, Elebring T, Hallnemo G, Andersson B, Svensson K, Carlsson A, Rollema H.
    J Med Chem; 1988 Jun 02; 31(6):1080-4. PubMed ID: 2967374
    [Abstract] [Full Text] [Related]

  • 29. 8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist.
    Arvidsson LE, Hacksell U, Nilsson JL, Hjorth S, Carlsson A, Lindberg P, Sanchez D, Wikstrom H.
    J Med Chem; 1981 Aug 02; 24(8):921-3. PubMed ID: 6460101
    [No Abstract] [Full Text] [Related]

  • 30. Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists.
    Grol CJ, Jansen LJ, Rollema H.
    J Med Chem; 1985 May 02; 28(5):679-83. PubMed ID: 4039369
    [Abstract] [Full Text] [Related]

  • 31. 8-Hydroxy-2-(alkylamino)tetralins and related compounds as central 5-hydroxytryptamine receptor agonists.
    Arvidsson LE, Hacksell U, Johansson AM, Nilsson JL, Lindberg P, Sanchez D, Wikström H, Svensson K, Hjorth S, Carlsson A.
    J Med Chem; 1984 Jan 02; 27(1):45-51. PubMed ID: 6418888
    [Abstract] [Full Text] [Related]

  • 32. Pentobarbital anaesthesia prevents the adrenaline-releasing effect of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin.
    Chaouloff F, Baudrie V, Laude D.
    Eur J Pharmacol; 1990 May 03; 180(1):175-8. PubMed ID: 2142092
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A homologous series of N-alkylated cis-(+)-(1 S, 2 R)-5-methoxy-1-methyl-2-aminotetralins: central dopamine receptor antagonists showing profiles ranging from classical antagonism to selectivity for autoreceptors.
    Svensson K, Carlsson A, Johansson AM, Arvidsson LE, Nilsson JL.
    J Neural Transm; 1986 May 03; 65(1):29-38. PubMed ID: 3958706
    [Abstract] [Full Text] [Related]

  • 37. The putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin antagonizes the antinociceptive effect of morphine.
    Berge OG, Fasmer OB, Ogren SO, Hole K.
    Neurosci Lett; 1985 Feb 28; 54(1):71-5. PubMed ID: 3156286
    [Abstract] [Full Text] [Related]

  • 38. Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands.
    Charifson PS, Bowen JP, Wyrick SD, Hoffman AJ, Cory M, McPhail AT, Mailman RB.
    J Med Chem; 1989 Sep 28; 32(9):2050-8. PubMed ID: 2527994
    [Abstract] [Full Text] [Related]

  • 39. Orally active central dopamine and serotonin receptor ligands: 5-, 6-, 7-, and 8-[[trifluoromethyl)sulfonyl]oxy]-2-(di-n-propylamino)tetralins and the formation of active metabolites in vivo.
    Sonesson C, Boije M, Svensson K, Ekman A, Carlsson A, Romero AG, Martin IJ, Duncan JN, King LJ, Wikström H.
    J Med Chem; 1993 Oct 29; 36(22):3409-16. PubMed ID: 8230131
    [Abstract] [Full Text] [Related]

  • 40. Conformational analysis of 2-aminoindans and 2-(aminomethyl)indans in relation to their central dopaminergic effects and a dynamic dopamine receptor concept.
    Wikström H, Lii JH, Allinger NL.
    J Med Chem; 1987 Jul 29; 30(7):1115-20. PubMed ID: 3599018
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.